Clinical Trial

Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will enroll patients who received neoadjuvant therapy for TNBC prior to surgery and did not get pCR. Given the relatively poor prognosis for these patients, this population is considered novel therapeutic as adjuvant treatment. Currently, capecitabine monotherapy could be beneficial to this group of patients according to CREATE-X trial results. The investigators are addressing the effect of anti-PD-L1, atezolizumab combined with capecitabine in patients with TNBC who did not get pCR after neoadjuvant chemotherapy compared to capecitabine monotherapy.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2018-11-26; most recent amendment 2026-04-21.
Status change: Recruiting → Active, Not Recruiting 2023-11-07
Status change: Not Yet Recruiting → Recruiting 2020-01-08
Trial Details
NCT Number NCT03756298
Lead Sponsor National Cancer Center, Korea
Conditions Triple Negative Breast Cancer
Enrollment 284 participants
Start Date 2019-01-15
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-23